GSK in talks to acquire cancer biotech Nuvalent for over $9 billion, FT reports
GSK is in talks to acquire cancer-focused biotech Nuvalent in a deal valued at more than $9 billion, according to the Financial Times.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
See this on the live map
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
46 of 68 central banks overshoot inflation goals, stoking market unease — First Squawk reports the data highlights persistent global price pressures.
46 of 68 central banks are overshooting their inflation targets, putting financial markets on edge.
Japan Finance Minister Satsuki Katayama says the country is undergoing its biggest budgetary reform since World War II.
Japan is currently undergoing the greatest budgetary reform process since the end of World War II, Finance Minister Satsuki Katayama says.
Paramount Skydance offers terms to settle California-led antitrust probe into its $110B Warner Bros. Discovery acquisition
Paramount Skydance has submitted suggested terms to resolve an antitrust investigation by California and other states into its $110 billion deal to buy Warner Bros. Discovery.
CBO estimates US faces $294 billion budget shortfall, highlighting growing fiscal pressure ahead of debt-ceiling negotiations.
The US may face a budget shortfall of $294 billion, according to a CBO estimate.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.